Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis

Published:2014-04-18 Issue:4 Volume:9 Page:e95473
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Li Xiao,Song Qiang,Chen Yu,Chang Chunkang,Wu Dong,Wu Lingyun,Su Jiying,Zhang Xi,Zhou Liyu,Song Luxi,Zhang Zheng,Xu Feng,Hou Ming

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference22 articles.

1. Alterations in DNA methylation: a fundamental aspect of neoplasia;SB Baylin;Adv Cancer Res,1998

2. Hypermethylation of tumor suppressor genes in cancer;JG Herman;Semin Cancer Biol,1999

3. Decitabine in the treatment of myelodysplastic syndromes;HI Saba;Ther Clin Risk Manag,2007

4. Characterization of DNA demethylation effects induced by 5-Aza-2′- deoxycytidine in patients with myelodysplastic syndrome;C Mund;Cancer Res,2005

5. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2-deoxycytidine (decitabine) in hematopoietic malignancies;JP Issa;Blood,2004

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Progress of Decitabine in Myelodysplastic Syndromes;Advances in Clinical Medicine;2024

2. Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study;Journal of Cancer;2021

3. Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases;Annals of Hematology;2020-09-17

4. Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy;Blood Cells, Molecules, and Diseases;2019-07

5. Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical setting;Leukemia & Lymphoma;2019-01-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3